The Role of Pharmacists in Identifying and Preventing Drug-Related Problems in PCOS Management

TL;DR

This paper discusses how pharmacists can help manage drug-related issues in PCOS treatment by improving medication use and patient care.

Contribution

The paper proposes a structured pharmaceutical care model for PCOS management involving pharmacists.

Findings

Common drug-related problems in PCOS include inappropriate dosing and prolonged therapy.

Pharmacists can improve adherence and monitor adverse events in PCOS patients.

Integrating pharmacists into care teams enhances treatment outcomes for PCOS.

Abstract

Polycystic ovary syndrome (PCOS) is an endocrine disorder prevalent in women of reproductive age, often requiring complex pharmacological management. The heterogeneity of the syndrome and the use of on- and off-label therapeutic agents—ranging from insulin sensitizers and ovulation inducers to oral contraceptives and herbal supplements—pose significant challenges, including adverse effects, drug interactions, and poor adherence. This narrative review explores the role of pharmacists in identifying and mitigating drug-related problems (DRPs) associated with PCOS therapy. Through thematic synthesis of the current literature, the study highlights common DRPs such as suboptimal drug selection, inappropriate dosing, prolonged therapy duration, and treatment-related safety concerns. It underscores the value of pharmacists’ interventions in enhancing medication adherence, optimizing therapeutic regimens, providing patient education, and monitoring adverse events. A structured, patient-level pharmaceutical care model is proposed, emphasizing personalized assessment, interdisciplinary collaboration, and continuous follow-up. The integration of clinical pharmacists into PCOS care teams has the potential to improve treatment effectiveness, patient satisfaction, and long-term health outcomes. Pharmacists’ contributions are especially critical given the widespread use of off-label therapies and supplements with variable evidence of benefit. Tailored pharmaceutical care can thus bridge the existing gaps in PCOS management and enhance the quality of life for the affected individuals.